• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations.关于 SARS-CoV-2 病毒复发的系统综述:频率、危险因素及可能的解释。
Infect Dis (Lond). 2021 May;53(5):315-324. doi: 10.1080/23744235.2020.1871066. Epub 2021 Jan 28.
2
Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies.弥补 COVID-19 诊断检测中的血清学差距:抗 SARS-CoV-2 IgA 抗体的价值。
J Med Virol. 2021 Mar;93(3):1436-1442. doi: 10.1002/jmv.26422. Epub 2020 Aug 21.
3
Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.日本一种新型自动化化学发光抗SARS-CoV-2 IgM和IgG抗体检测系统的验证,该系统可同时检测N蛋白和S蛋白。
PLoS One. 2021 Mar 4;16(3):e0247711. doi: 10.1371/journal.pone.0247711. eCollection 2021.
4
Possible vertical transmission and antibodies against SARS-CoV-2 among infants born to mothers with COVID-19: A living systematic review.可能存在 COVID-19 母亲所生婴儿的垂直传播和针对 SARS-CoV-2 的抗体:一项实时系统评价。
J Med Virol. 2021 Mar;93(3):1361-1369. doi: 10.1002/jmv.26622. Epub 2020 Nov 10.
5
Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.感染后 13 个月 SARS-CoV-2 特异性抗体的持续存在。
Viruses. 2021 Nov 19;13(11):2313. doi: 10.3390/v13112313.
6
Clinical characteristics and potential factors for recurrence of positive SARS-CoV-2 RNA in convalescent patients: a retrospective cohort study.恢复期患者 SARS-CoV-2 RNA 复阳的临床特征及潜在影响因素:一项回顾性队列研究。
Clin Exp Med. 2021 Aug;21(3):361-367. doi: 10.1007/s10238-021-00687-y. Epub 2021 Feb 4.
7
Serological assay for anti-SARS-CoV-2 antibodies improves sensitivity of diagnosis of COVID-19 patients.血清学检测抗 SARS-CoV-2 抗体可提高 COVID-19 患者诊断的灵敏度。
Med Microbiol Immunol. 2021 Dec;210(5-6):283-289. doi: 10.1007/s00430-021-00721-6. Epub 2021 Sep 25.
8
The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19.新型冠状病毒肺炎患者血清 IgM 和 IgG 对 SARS-CoV-2 的动态变化。
J Med Virol. 2021 Feb;93(2):924-933. doi: 10.1002/jmv.26353. Epub 2020 Sep 28.
9
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.在无症状至轻症 COVID-19 感染至少 8 个月后,仍能产生强大的体液和细胞免疫反应,并降低再次感染的风险。
J Intern Med. 2022 Jan;291(1):72-80. doi: 10.1111/joim.13387. Epub 2021 Sep 27.
10
Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.酶联免疫吸附试验评价 COVID-19 患者血清 IgM 和 IgG 抗体。
J Med Virol. 2021 May;93(5):2857-2866. doi: 10.1002/jmv.26741. Epub 2021 Mar 1.

引用本文的文献

1
Predicting higher risk factors for COVID-19 short-term reinfection in patients with rheumatic diseases: a modeling study based on XGBoost algorithm.预测风湿性疾病患者COVID-19短期再感染的高风险因素:一项基于XGBoost算法的建模研究。
J Transl Med. 2024 Dec 24;22(1):1144. doi: 10.1186/s12967-024-05982-2.
2
Rate and Risk Factors of Reinfection, Recurrence, and Hospital Readmission Among SARS-Cov-2 Hospitalized Patients; a National Cohort Study.新冠病毒住院患者再次感染、复发及再次入院的发生率和危险因素;一项全国队列研究。
Arch Acad Emerg Med. 2024 Jun 22;12(1):e55. doi: 10.22037/aaem.v12i1.2327. eCollection 2024.
3
Pathophysiological Mechanisms in Long COVID: A Mixed Method Systematic Review.“长新冠”的病理生理机制:一项混合方法的系统评价
Int J Environ Res Public Health. 2024 Apr 12;21(4):473. doi: 10.3390/ijerph21040473.
4
Safety and efficiency of COVID-19 vaccine in North Africa.北非地区 COVID-19 疫苗的安全性和有效性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2306703. doi: 10.1080/21645515.2024.2306703. Epub 2024 Feb 2.
5
How immune breakthroughs could slow disease progression and improve prognosis in COVID-19 patients: a retrospective study.免疫突破如何减缓 COVID-19 患者的疾病进展并改善预后:一项回顾性研究。
Front Immunol. 2023 Oct 23;14:1246751. doi: 10.3389/fimmu.2023.1246751. eCollection 2023.
6
Evaluation of the Factors Associated with Reinfections towards SARS-CoV-2 Using a Case Control Design.采用病例对照设计评估与新型冠状病毒再次感染相关的因素。
J Clin Med. 2023 Jun 5;12(11):3861. doi: 10.3390/jcm12113861.
7
What contributes to the re-positive nucleic acid test results for the omicron variant of SARS-CoV-2 in the shelter cabin hospital in Shanghai, China?在中国上海方舱医院中,导致新冠病毒奥密克戎变异株核酸检测结果再次呈阳性的原因是什么?
Heliyon. 2023 May;9(5):e15679. doi: 10.1016/j.heliyon.2023.e15679. Epub 2023 Apr 24.
8
Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis.全球 2019 冠状病毒病再感染的流行率:系统评价和荟萃分析。
BMC Public Health. 2023 Apr 28;23(1):778. doi: 10.1186/s12889-023-15626-7.
9
SARS-CoV-2 reinfection across a spectrum of immunological states.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在一系列免疫状态下的再次感染。
Health Sci Rep. 2022 Jul 22;5(4):e554. doi: 10.1002/hsr2.554. eCollection 2022 Jul.
10
Characteristics of 24 SARS-CoV-2-Sequenced Reinfection Cases in a Tertiary Hospital in Spain.西班牙一家三级医院24例新冠病毒测序再感染病例的特征
Front Microbiol. 2022 May 26;13:876409. doi: 10.3389/fmicb.2022.876409. eCollection 2022.

本文引用的文献

1
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis.血清学证据表明人类感染 SARS-CoV-2:系统评价和荟萃分析。
Lancet Glob Health. 2021 May;9(5):e598-e609. doi: 10.1016/S2214-109X(21)00026-7. Epub 2021 Mar 8.
2
Evidence of SARS-CoV-2 re-infection with a different genotype.新型冠状病毒 2 型(SARS-CoV-2)再次感染不同基因型的证据。
J Infect. 2021 Apr;82(4):84-123. doi: 10.1016/j.jinf.2020.11.011. Epub 2020 Nov 15.
3
Epidemiological and Clinical Findings of Short-Term Recurrence of Severe Acute Respiratory Syndrome Coronavirus 2 Ribonucleic Acid Polymerase Chain Reaction Positivity in 1282 Discharged Coronavirus Disease 2019 Cases: A Multicenter, Retrospective, Observational Study.1282例新型冠状病毒肺炎出院患者严重急性呼吸综合征冠状病毒2核糖核酸聚合酶链反应阳性短期复发的流行病学和临床研究:一项多中心、回顾性、观察性研究
Open Forum Infect Dis. 2020 Sep 13;7(10):ofaa432. doi: 10.1093/ofid/ofaa432. eCollection 2020 Oct.
4
Positive RT-PCR Test Results in 420 Patients Recovered From COVID-19 in Wuhan: An Observational Study.武汉420例新冠肺炎康复患者的RT-PCR检测结果呈阳性:一项观察性研究。
Front Pharmacol. 2020 Oct 7;11:549117. doi: 10.3389/fphar.2020.549117. eCollection 2020.
5
SARS-CoV-2 re-infection: a case report from Qatar.严重急性呼吸综合征冠状病毒2型再次感染:卡塔尔的一例病例报告。
J Infect. 2021 Mar;82(3):414-451. doi: 10.1016/j.jinf.2020.10.019. Epub 2020 Oct 25.
6
Genomic evidence for reinfection with SARS-CoV-2: a case study.基因组证据表明 SARS-CoV-2 再次感染:一项案例研究。
Lancet Infect Dis. 2021 Jan;21(1):52-58. doi: 10.1016/S1473-3099(20)30764-7. Epub 2020 Oct 12.
7
Characteristics of recovered COVID-19 patients with recurrent positive RT-PCR findings in Wuhan, China: a retrospective study.中国武汉新冠病毒核酸检测复阳康复患者的特征:一项回顾性研究
BMC Infect Dis. 2020 Oct 13;20(1):749. doi: 10.1186/s12879-020-05463-z.
8
Reactivation of SARS-CoV-2 after Asymptomatic Infection while on High-Dose Corticosteroids. Case Report.大剂量糖皮质激素治疗期间无症状感染后新冠病毒的再激活。病例报告。
SN Compr Clin Med. 2020;2(11):2402-2405. doi: 10.1007/s42399-020-00548-x. Epub 2020 Oct 2.
9
Is recurrence possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of literature.新冠病毒病 2019(COVID-19)是否会复发?病例系列和文献系统评价。
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):1-12. doi: 10.1007/s10096-020-04057-6. Epub 2020 Oct 10.
10
The first case of documented Covid-19 reinfection in Israel.以色列首例有记录的新冠病毒再次感染病例。
IDCases. 2020;22:e00970. doi: 10.1016/j.idcr.2020.e00970. Epub 2020 Oct 1.

关于 SARS-CoV-2 病毒复发的系统综述:频率、危险因素及可能的解释。

A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations.

机构信息

Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Infect Dis (Lond). 2021 May;53(5):315-324. doi: 10.1080/23744235.2020.1871066. Epub 2021 Jan 28.

DOI:10.1080/23744235.2020.1871066
PMID:33508989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7852280/
Abstract

BACKGROUND

Since late 2019, SARS-CoV-2 which leads to coronavirus disease 2019 (COVID-19), has caused thousands of deaths. There are some pieces of evidence that SARS-CoV-2 genome could be re-detectable in recovered patients.

METHODS

We performed a systematic review in the PubMed/Medline database to address the risk of SARS-CoV-2 recurrence. The last update was for 20 November 2020. Among the 1178 initially found articles, 66 met the inclusion criteria and were considered.

FINDINGS

In total, 1128 patients with at least one-time recurrence of SARS-CoV-2 were included. Recurrence rate has been reported between 2.3% and 21.4% in cohort studies, within a mean of 20 (ranged 1-98) days after discharge; younger patients are being affected more. Following the second course of disease, the disease severity decreased or remained unchanged in 97.3% while it increased in 2.6%. Anti-SARS-CoV-2 IgG and IgM were positive in 11-95% and 58.8-100%, respectively. Based on the literature, three possibilities include reactivation of previous disease, reinfection with the same virus, and false negative, which have been discussed in details.

CONCLUSION

There is a relatively notable risk of disease recurrence in previously recovered patients, even those who are immunised against the virus. More studies are required to clarify the underlying cause of this phenomenon.

摘要

背景

自 2019 年底以来,导致 2019 年冠状病毒病(COVID-19)的 SARS-CoV-2 已导致数千人死亡。有一些证据表明,SARS-CoV-2 基因组在已康复的患者中可能再次被检测到。

方法

我们在 PubMed/Medline 数据库中进行了系统评价,以确定 SARS-CoV-2 复发的风险。最后一次更新时间为 2020 年 11 月 20 日。在最初发现的 1178 篇文章中,有 66 篇符合纳入标准并被考虑在内。

结果

共有 1128 例至少有一次 SARS-CoV-2 复发的患者被纳入。在队列研究中,复发率报告在 2.3%至 21.4%之间,平均在出院后 20 天(范围为 1-98 天)内;年轻患者受影响更大。在第二次发病后,97.3%的患者病情严重程度减轻或保持不变,2.6%的患者病情加重。抗 SARS-CoV-2 IgG 和 IgM 的阳性率分别为 11%-95%和 58.8%-100%。根据文献,有三种可能性,包括先前疾病的再激活、同一病毒的再感染和假阴性,对此已进行了详细讨论。

结论

先前已康复的患者存在相当显著的疾病复发风险,即使这些患者对该病毒有免疫力。需要进一步研究来阐明这种现象的根本原因。